{"id":"NCT00938717","sponsor":"Ironwood Pharmaceuticals, Inc.","briefTitle":"Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide Administered Orally for 26 Weeks in Patients With Irritable Bowel Syndrome With Constipation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2010-09","completion":"2010-09","firstPosted":"2009-07-14","resultsPosted":"2013-01-30","lastUpdate":"2013-11-05"},"enrollment":805,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Irritable Bowel Syndrome With Constipation"],"interventions":[{"type":"DRUG","name":"Linaclotide or Matching Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"290 Î¼g Linaclotide","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the safety and efficacy of linaclotide administered to patients with Irritable Bowel Syndrome with Constipation (IBS-C).","primaryOutcome":{"measure":"Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks","timeFrame":"Change from Baseline to Week 12","effectByArm":[{"arm":"Placebo","deltaMin":12,"sd":null},{"arm":"Linaclotide","deltaMin":51,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":107,"countries":["United States"]},"refs":{"pmids":["24075889","23116208"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":403},"commonTop":["Diarrhea","Sinusitis","Nausea","Upper respiratory tract infection","Urinary tract infection"]}}